Briefs: Nectar Lifesciences, Cipla and Marksans Pharma

Marksans Pharma gets USFDA nod for acid reflux drug

Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr

Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore

Imfinzi granted Priority Review and Breakthrough Therapy Designation in US

For patients with resectable early-stage gastric and gastroesophageal junction cancers

Roche updates on Elevidys gene therapy for Duchenne muscular dystrophy in EU

Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne

AstraZeneca’s Tagrisso plus chemotherapy improves overall survival in EGFR-mutated advanced lung cancer

Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty

EU launches strategies to strengthen crisis readiness and health security

The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises

Nectar Lifesciences sell API and formulations business to Ceph Lifesciences for Rs. 1,270 Cr

Bemarituzumab Plus chemo improves overall survival in FGFR2b+ gastric cancer

New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options

Glenmark Pharmaceuticals launches TEVIMBRA in India

TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)